Goldman Sachs
ANVS icon

Goldman Sachs’s Annovis Bio ANVS Stock Holding History

Goldman Sachs’s Portfolio ANVS Stock Details ANVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,273
Closed -$181K – 6551
2021
Q4 		$181K Buy
+10,273
New +$265K ﹤0.01% 5942
2021
Q3 		– Sell
-25,819
Closed -$2.21M – 6201
2021
Q2 		$2.21M Buy
+25,819
New +$1.19M ﹤0.01% 4110

Other funds holding ANVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WFAG
Wescott Financial Advisory Group Philadelphia, Pennsylvania $1.14B AUM 16.59% 1-Year Est. Return
MWM
Modera Wealth Management Westwood, New Jersey $8.34B AUM 19.68% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs's ANVS Position: Q1 2022 in Review

Goldman Sachs sold out of Annovis Bio (ANVS) in Q1 2022, closing a stake of 10,273 shares — an estimated $181K sold.

Goldman Sachs first reported a position in ANVS in Q2 2021 and held it in 2 quarters. The position peaked at $2.21M in Q2 2021. 24 funds tracked by Wall St. Rank hold ANVS as of Q1 2022.

  • Goldman Sachs reported no remaining Annovis Bio position as of Q1 2022 after selling out during the quarter.
  • Goldman Sachs sold 10,273 Annovis Bio shares in Q1 2022, an estimated $181K.
  • Goldman Sachs first reported a position in Annovis Bio in Q2 2021 and held it in 2 quarters.
  • Goldman Sachs's Annovis Bio position peaked at $2.21M in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.